Dec 31, 2023

Semler Scientific Q4 2023 Earnings Report

Semler Scientific reported an increase in revenue and net income for Q4 2023.

Key Takeaways

Semler Scientific reported Q4 2023 revenues of $15.1 million, a 9% increase year-over-year, and net income of $4.2 million, a 31% increase year-over-year. The company's cash balance increased to $57.3 million. They are seeking FDA clearance with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.

Fourth quarter revenues increased by 9% to $15.1 million.

Fourth quarter net income increased by 31% to $4.2 million.

Full year revenues increased by 20% to $68.2 million.

Cash balance increased to $57.3 million.

Total Revenue
$15.1M
Previous year: $13.8M
+9.1%
EPS
$0.55
Previous year: $0.41
+34.1%
Gross Profit
$11.7M
Previous year: $12.6M
-7.5%
Cash and Equivalents
$57.2M
Previous year: $23M
+148.5%
Free Cash Flow
$4.7M
Previous year: $1.62M
+189.6%
Total Assets
$78.1M
Previous year: $62.7M
+24.5%

Semler Scientific

Semler Scientific

Forward Guidance

Semler Scientific remains focused on marketing its product and seeking a new 510(k) clearance from the FDA with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.